skip to Main Content

FIRST BLOCKCHAIN BIOTECH ECOSYSTEM

Be part of a company with a multi-billion dollar potential

Pre-Sale
Successfully
Finished!

Total Raised: $883.323
530.02 ETH + 141.4643 BTC

Get 1 Free ARNA Token!

For anyone who leaves email. 1 ARNA token is 0.000266 ETH

[[[["field1","contains","gmail"]],[["show_fields","field8"]],"and"]]
1
Have a promo code?
Gmail might put our email with instructions in Promotions folder!
Are you US or China resident?
Previous
Next

or fill out the Waitlist form

What is the token functionality

  1. 10 tokens from the main sale event (0.000266 ETH — for 1 token, and 0.00266 ETH — for 10 tokens) can be used to purchase 1 ARNA BC test. Anticipated average market price of one ARNA BC test is 0.33333 ETH.
  2. Holders of large amounts of tokens will be eligible to participate in ARNA VIP Reward Program, offering unprecedented opportunity.
  3. ARNA tokens will be used on ARNA Panacea platform as cryptocurrency for payments between platform participants.
  4. Researchers will be able to conduct “crowdfunding” events on their breakthrough inventions in biotech.
  5. …and other use – read more in our White paper.

“I personally believe, like many other people, that the clinical trial system we have right now is broken. It isn’t working to meet the objectives that we need it for,” – Janet Woodcock, director of the Center for Drug Evaluation and Research at the Food and Drug Administration

What is ARNA

ARNA Advisor Dmitry Kulish tells about ARNA project and blockchain. Full Interview

ARNA Genomics Intro

Introducing ARNA Panacea

ARNA Panacea is a Biotech Decentralized Solution, Powered by Blockchain & ARNA Tokens

ARNA Panacea by design is a platform which allows not only processing of clinical trials data but also support for researchers during R&D phase and marketplace for all types of market participants involved in clinical trials as well as direct sales of final biotech products to customers (patients).

site_img

Your Chance to enter in Biotech Market

ARNA Genomics is the innovative biotechnological company engaged in R&D and launching on market methods of oncological diseases early detection using blockchain-ecosystem ARNA Panacea

ARNA BC is the first test developed product for early detection of breast cancer with a high-precision.

Product Overview

ARNA BC and Cancer Market Overview

OUR VISION

to revolutionize the way disruptive biotech technologies aimed to fight cancer are launched to the mass-market with the use of Blockchain technologies

OUR MARKET IS HUGE…

1B

women annually globally

1000s

Thousands of biotech Researchers

40M

ARNA BC Tests only in US & Russia

$150B+

M&A deals on medical market during each of the last 3 years

ARNA Panacea

community roles

MVP participants

ARNA Panacea use cases

Proof Of Research

Proof of research

The Data stored in the public blockchain ARNA Panacea will be the basis of the evidence base.

Protected Research

Protected research

The ability to “scientific research” in a secure format using encrypted key in blockchain ecosystem

Big Data

Big Data

Global access to the accumulated array of information through an open API interface with the functionality required to analyze the available data.

Ecosystem

Ecosystem

A single blockchain platform for collecting, storing and analyzing information methods of diagnosis and treatment of cancer

Smart Blockchain

Smart Blockchain

The possibility of connecting an AI to search for “patterns” for developing new methods of cancer treatment

ARNA Tokens

ARNA Tokens

Usage through interaction within the ecosystem of patients, researchers, Regulator, CRO, pharmaceutical companies, clinics

Token details:

Role of token:

ARNA BC test purchase, ARNA Panacea data access, R&D rewarding

Token supply:

1 billion

Token Distribution Event:

500 million (50%)

Symbol:

ARNA

Initial value:

1 ARNA token = 0.000266 ETH

Tokens:

Ethereum ERC20

Token Distribution Event details:

Sale period:

19 november - 03 december

Token distribution date:

21 december 2017

Accepted currencies:

ETH

Soft cap:

3 333 ETH

Maximum cap (approx.):

130 000 ETH

How funds are held:

Wallet held by team

Unsold tokens policy:

Transferred into marketing budget

Minimum viable product:

ARNA Panacea

TOKENS AND FUNDS

Token allocation

  • 50% sold in the token sale
  • 25% to incentivize the ecosystem
  • 24% retained by ARNA Genomics
  • 1% to cover tokensale

Distribution of TDE funds

  • ARNA BC - 50%
  • ARNA Panacea - 17%
  • R&D - 14%
  • OPEX incl. marketing - 13%
  • Legal costs - 5%

TEAM

Egor Melnikov

Egor Melnikov

Founder, CEO

More than 10 years ago started the project with mission to save lives from cancer. Economist and manager by education, entrepreneur by experience and spirit. Made several successful startups as founder and co-founder in advertising and production business, international logistics, IT solutions for large-scale projects, was CEO of international telecom operator. ARNA – is the meaning of Egor’s life.

George Nikitin

George Nikitin

Co-founder and COO, blockchain platform ideologist

Master of physics (diploma with honors), have 14 articles and inventions. Successfully worked in large international companies (Delloite, etc.), as well as in private equity companies. He has extensive experience as executive manager in various major private and public companies in IT, telecom, oil&gas.

Anatoliy Melnikov

Anatoliy Melnikov

Co-founder and HEAD of R&D, creator of ARNA tests

Having more than 40 years of experience in molecular biology and genetics, he is the author and co-author of more than 50 scientific articles and number of patents. For 15 years he worked in the USA in oncological centers, before that – in Canada, Hungary in various scientific companies, and Russia – a branch of the Institute of Bioorganic Chemistry of the Russian Academy of Sciences and the Institute of Biochemistry and Physiology of Microorganisms of the Russian Academy of Sciences. He graduated from the biological faculty of the Lomonosov Moscow State University.

Ilya Senechkin

Ilya Senechkin

PhD in Life Sciences, Embryology Director ("Center IVF" network of clinics, Russia)

Development Manager for Scientific and Educational Programs (F. Paulsen Assisted Reproductive Technologies Center, Russian Ministry of Health). Former: medical advisor (MC Femina, Vitrolife), clinical embryologist (MD Medical Group), Jr. scientist (Wageningen University, The Netherlands)

Sergey Chernyshev

Sergey Chernyshev

Deputy head of R&D, PhD

Branch of the Institute of Bioorganic Chemistry Acad. M.M. Shemyakin and A. Ovchinnikov Institute of Sciences, Pushchino. Specialization — molecular biology, biotechnology, genetic engineering. Area of scientific expertise: regulation of gene expression, transcription, translation, molecular mechanisms of bacterial phage lysis.

Magomed Chatuev

Magomed Chatuev

Software architect and developer

Software architect and developer. Has a big experience working with start-ups in the areas of e-commerce, PR & Marketing, finance, transportation, ERP development. Mainly focused on building SaaS, APIs & complex business processes automation. Had been working in international companies in Russia, Ireland, and Germany.

Alexander Mazaletskiy

Alexander Mazaletskiy

Software Architect

Founder, CEO and Principal engineer in blockchain integrator Dicoiner (www.dicoiner.com) Founder and CEO in mobile development studio Zero Cool Team. 10 years experience in enterprise fintech software design and development. Last two yeast making research and implementation of blockchain systems. Graduate of IIDF-2015(Internet Initiatives Development Fund) in the team of Teslawatch startup.
15 scientific publications in the field of natural language processing

Sergey Dolgachev

Sergey Dolgachev

Co-founder, head of finance and risks management

Entrepreneur and co-owner of several companies in the oilfield service, medicine and biotech. He graduated from the Faculty of Computational Mathematics and Cybernetics of the Moscow State University Lomonosov, EMBA Higher School of Economics, studied at the Skolkovo Management School, INSEAD and graduate school of MGIMO. He has extensive executive experience in oil&gas public and private companies.

Vladimir Savanovich

Vladimir Savanovich

Co-founder, Head of Investor Relations

has a master’s degree in physics. During his professional experience, he worked in various business areas, mainly focusing on the active development of the contractual base of enterprises. He has experience in working in a Western consulting company, a resort development company, a Swiss investment fund and a Russian exploration company.

ADVISORS

Dmitry Kulish

Dmitry Kulish

Dmitry Kulish is an independent expert in the fields of strategic, organizational and technological development of pharmaceutical products. Dmitry holds a PhD in Biology, has been a postdoc at Harvard Medical School, earned MBA from the Wharton Business School, the Institute of Molecular Genetics of the Russian Academy of Sciences, and the Moscow State Institute of Molecular Biology Lomonosov Moscow State University.

Ph.D DR. Soenke Bartling

Ph.D DR. Soenke Bartling

Ph.D DR. MED, Board certified Radiologist, blockchain for research & healthcare / Open Science. Sönke has a tremendous background in neuroradiology at Hannover Medical School, Institute for Radiology and Interventional Therapy and other sound scientific organizations. Apart from that Sönke is well-known due to his activity in Web 2.0 for science in 00x, following by working on Blockchain for Science and Open Science (awarded in 2015, Germany land of ideas) concepts. He is author of more than 20 scientific publications, number of reviews, books and 6 patents. Holds various awards and is a member of governmental groups on radiology and tomography.
Sergey Borovskiy

Sergey Borovskiy

worked and lived in China since 1991. He has more than 20 years of experience in international management in China and Hong Kong. He held the positions of Chairman of the Board of Directors in various companies in China involved in international trade, investment and production. Since 2017, he was the General Manager of Sanju Environmental Protection (Hong Kong) Limited, coordinating the international projects of the controlling shareholder.

Alex Kosik

Alex Kosik

Dr. Alex Kоsik is a successful serial technology entrepreneur. His focus is in Life Sciences, Medical Devices, FDA Compliance, Evidence-Based Medicine, Venture Capital and M&A. Alex is a recognized technology due diligence expert and senior analyst to several VC’s, angels, Gerson Lehrman Group and institutional investors. He co-founded multiple businesses himself, met Bill Gates, sold his “G1 Gravitonus workstations” to Forbes-100, and ranked 3rd by Becker’s Spine Review of “10 spine orthopedic surgeon tech entrepreneurs to know”

Dmitry Grigoriev

Dmitry Grigoriev

Over 20 years of successful general management experience with a particular focus on business development and operational excellence. Сonstant over 5 years trend in business development and financial results improvement for large European integrated company with over 8 bln. USD in turnover and presence in over 15 countries. Has implemented several very successful business alliances strategies where the managed companies/clients have benefited from new distribution channels/partners reach.

Mikhail Groubman

Mikhail Groubman

Mikhail joined Atlant Clinical in 2012 as Chief Executive Officer and as a member of the Board of Directors. Prior to Atlant Clinical he worked at GlaxoSmithKline where he started as a clinical research assistant, later becoming a local study manager in the oncology group. He subsequently joined the Moscow Sales Department, where he rose to become Regional Market Access Director. Mikhail graduated from Lomonosov Moscow State University with Master degrees in biochemistry and management.

Marina Sekacheva

Marina Sekacheva

is a Doctor of Medical Sciences, a laureate of the Russian Government Prize in Science, a holder of post-doctoral degree in medicine of the Technical University of Munich, the Director of the Center for Personalized Oncology Sechenov OncoTarget, established as part of the Institute of Personalized Medicine in 2017

Ilya N. Chistyakov

Ilya N. Chistyakov

MD., PhD, founder and CEO of the Preclinical Study Centre LLC, managing company of “Pharma Valley” biotechnological cluster – the only GLP OECD in Russia, an independent hybrid CRO specialized on conducting a full cycle of pharmacological development, manufacturing, preclinical and clinical studies of biotechnological, biosimilar and generic medicines.

Ed Kanalosh

Ed Kanalosh

has more than 20 years of experience in biotech investments and strategic consulting. Partner of venture fund “Maxwell Biotech” (Moscow), director of consulting company Candesic (London). Edward is an acting head of Investment Service of Skolkovo fund, vice-president of Investment Bank “Trust” and consultant of New Jersey office of McKinsey company. His career has started in Bill and Melinda Gates Foundation Fund. MBA from Harvard Business School, MD with PhD.

ROADMAP

2013
2013_en

ARNA Genomics was established

Obtained status of a member of the Skolkovo biomedical cluster

2014
2014_en

Seed round;
Development of ARNA-Thermometr, a test for the presence of oncological diseases;
“Know-how” objects formalization

2015
2015_en

Development of ARNA Breast Cancer — a high-precision test for early detection of breast cancer

2016
2016_en

Development of ARNA Colon Cancer;
ARNA BC development is completed;
Beginning of laboratory tests of ARNA BC;
Submission of patent application No 1

2017
2017_en

End of laboratory tests of ARNA BC;
Start of ARNA BC clinical research jointly with Sechenov University;
Submission of application of Patent Cooperation Treaty No 1;
Token Distribution Event

2018
2018_en

Opening of the office and the 1st laboratory unit in the USA.
Submission of application of Patent Cooperation Treaty No 2 and 3.
Agreement of the regulatory strategy for ARNA BC. Launch of clinical research No 1 in the USA with FDA.
ARNA CC development is completed, starting laboratory research.
ARNA Panacea – launch of the beta version of blockchain-ecosystem, basic documentation for developers.

2019
2019_en

Using of ARNA Panacea’s blockchain ecosystem by interested market players (regulators, investors, users, etc.)
Start of development: ARNA Lung, ARNA Liver, ARNA Pancreas;
ARNA BC’s entry into the US market;
Clinical trials in China;
National phases: USA, China, India, EU, UK, Israel, Brazil;
Seed round B;
Receiving the first revenue.

PARTNERS

ernst-young-ey-1-min
emblema_med_akademii_sechenova
logo
skolkovoit-180x129
IMAGE

MEDIA

logo-300×77

Arna Genomics Introduces A Revolutionary Solution For Cancer Diagnostics And Treatment Biotechnologies – Blockchain Ecosystem Arna Panacea.

ARNA Panacea by design is platform which allows not only processing of clinical trials data but also support for researchers during R&D phase and marketplace for all types of market participants involved in clinical trials as well as direct sales of final biotech products to customers (patients)…READ MORE

steemit

ARNA Panacea — Blockchain Biotech Ecosystem
ARNA Genomics introduces a revolutionary solution for cancer diagnostics and treatment biotechnologies — blockchain-ecosystem ARNA Panacea.
ARNA Panacea by design is platform which allows not only processing of clinical trials data but also support for researchers during R&D phase and marketplace for all types of market participants involved in clinical trials as well as direct sales of final biotech products to customers (patients)… READ MORE

NewsBTC-Logo

ARNA Genomics Develops Blockchain Powered Cancer Research Solution, Announces ICO

ABitcoin has not just revolutionized the global financial system, but it seems to be on its way to changing the healthcare industry as well. ARNA Genomics, a Russian biotechnology company, is demonstrating the potential of blockchain in healthcare with its ARNA Panacea platform… READ MORE

logo-home-new
forclog
coin-min
logo
Безымянный
tokenmarket
coingecko-logo
cryptocoinsnews-vector-kopi-1-1
smith+crown
3423420